Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
Hirani
Vandana N
VN
Institute for Biomedical Research, Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ 07601, USA.
Raucy
Judy L
JL
Lasker
Jerome M
JM
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D001711:Biotransformation; D065731:Cytochrome P-450 CYP2C19; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics*; D006801:Humans; D006900:Hydroxylation; D066298:In Vitro Techniques; D007700:Kinetics; D008862:Microsomes, Liver / Q000378:metabolism*; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D019888:Nelfinavir / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics*; D009853:Omeprazole / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D004791:Enzyme Inhibitors; D017320:HIV Protease Inhibitors; C495123:hydroxy-t-butylamidenelfinavir; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019888:Nelfinavir; D009853:Omeprazole